Pancreatic ductal adenocarcinoma is projected to become the second-leading cause of cancer death in the United States by 2030 ...

Pancreatic ductal adenocarcinoma is projected to become the second-leading cause of cancer death in the United States by 2030 ...

Oncolytics Biotech ( ($ONCY) ) has shared an update. Oncolytics Biotech Inc. announced on November 19, 2025, that it has aligned with the FDA on ...

This retrospective cohort study used data from the Veterans Health Administration to assess the association between chronic untreated HCV and incident PDAC and whether different HCV genotypes affect ...

Main pancreatic duct (MPD) dilation without an apparent obstructing lesion is an independent risk factor for neoplastic ...

Please provide your email address to receive an email when new articles are posted on . An irinotecan liposome injection regimen improved OS compared with standard chemotherapy among untreated ...

Dr. Melvin Silverstein answers the question: 'What's Invasive Ductal Carcinoma?' — -- Question: What is invasive ductal carcinoma? Answer: Invasive ductal carcinoma is the most common type of ...

Ductal adenocarcinoma of the prostate is a rare, yet aggressive, subtype of prostate cancer that diverges in clinicopathological and genomic characteristics from the more common acinar adenocarcinoma.

During a routine mammogram, doctors found something unusual in Patty Schone’s left breast. But the real danger was actually ...

Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced alignment with the U.S. Food and Drug ...